Two stocks in Healthcare
Genmab A/S vs Novo Nordisk A/S: profit, growth, debt and price compared
Genmab A/S and Novo Nordisk A/S are each stronger on 3 of 6 figures: Genmab A/S on sales growth, analysts' view and price trend; Novo Nordisk A/S on profit margin, debt and price for its expected profit.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Genmab A/SGMAB.CO | Novo Nordisk A/SNOVO-B.CO | |
|---|---|---|
| Net margin | 17.0% | Stronger: 33.9% |
| Revenue growth, past year | Stronger: +16.10% | +5.60% |
| Debt to equity | 82.1% | Stronger: 61.7% |
| Forward P/E | 29.9× | Stronger: 12.0× |
| Dividend yield | — | 4.25% |
| Analysts | Stronger: Strong buy · 13 | Hold · 24 |
| From its 200-day average | Stronger: +54.9% | −7.0% |
Share price over the past year
- Genmab A/S+78.0%
- Novo Nordisk A/S−14.8%
13 Nov 202518 Nov 2026
Genmab A/S or Novo Nordisk A/S: which is stronger?
- NOVO-B.CO
Which is more profitable?
Novo Nordisk A/S keeps more of each sale as profit: 33.9% against 17.0%.
- GMAB.CO
Which is growing its sales faster?
Genmab A/S is growing its sales faster: +16.10% over the past year, against +5.60%.
- NOVO-B.CO
Which has borrowed less?
Novo Nordisk A/S has borrowed less: its debt is 61.7% of what its shareholders own, against 82.1% for Genmab A/S.
- NOVO-B.CO
Which costs less for the profit it is expected to make?
Novo Nordisk A/S costs less for the profit it is expected to make: 12.0× its forward earnings, against 29.9×.
Which pays more in dividends?
Novo Nordisk A/S pays 4.25% a year in dividends for what a share costs, where Genmab A/S pays none.
- GMAB.CO
Which do analysts rate higher?
Analysts are warmer on Genmab A/S: Strong buy, against Hold for Novo Nordisk A/S.
- GMAB.CO
Which is in the stronger price trend?
Genmab A/S' price is in the stronger trend: 54.9% above its 200-day average, against 7.0% below.
What each company does
GMAB.COGenmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Reports results on 16 February 2027
NOVO-B.CONovo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Reports results on 3 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.